📊 BCAX Key Takeaways
Investment Thesis
Bicara Therapeutics is a pre-revenue biotech company with significant cash burn and no commercial revenue, making it a high-risk investment dependent entirely on pipeline success. With $82.9M in annual operating cash outflows against only $171.7M in cash reserves, the company has approximately 2 years of runway at current burn rates before facing potential dilution or additional financing. The company's negative ROE of -25% and ROA of -23.7% reflect the capital-intensive nature of early-stage drug development with no offsetting revenue generation.
BCAX Strengths
- Strong liquidity position with $171.7M in cash and 14.14x current ratio providing runway for clinical trials
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial distress risk
- Substantial stockholders' equity of $402.8M providing balance sheet cushion
BCAX Risks
- Pre-revenue model with -$100.6M net loss and -$83.0M free cash flow indicating unsustainable burn rate
- Approximately 2-year cash runway at current $82.9M annual operating burn rate requiring near-term financing or major clinical success
- Biotech execution risk: company dependent on pipeline drug approval with no guarantee of success or commercialization
- 19 insider Form 4 filings in 90 days suggest potential equity compensation dilution pressures
Key Metrics to Watch
- Monthly cash burn rate and quarters of cash remaining until potential financing need
- Clinical trial progress and FDA interactions for lead candidates
- Insider selling vs. equity compensation patterns indicating insider confidence levels
BCAX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 14.14x current ratio provides a solid financial cushion.
BCAX Profitability Ratios
BCAX vs Healthcare Sector
How Bicara Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BCAX Balance Sheet & Liquidity
BCAX 5-Year Financial Trend
5-Year Trend Summary: Bicara Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-89.61 indicates the company is currently unprofitable.
BCAX Growth Metrics (YoY)
BCAX Capital Allocation
BCAX SEC Filings
Access official SEC EDGAR filings for Bicara Therapeutics Inc. (CIK: 0002023658)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773783415.xml | View → |
| Mar 11, 2026 | 4 | xslF345X05/wk-form4_1773262035.xml | View → |
| Mar 6, 2026 | 4 | xslF345X05/wk-form4_1772843254.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/wk-form4_1772755827.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/wk-form4_1772755729.xml | View → |
❓ Frequently Asked Questions about BCAX
What is the AI rating for BCAX?
Bicara Therapeutics Inc. (BCAX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCAX's key strengths?
Strong liquidity position with $171.7M in cash and 14.14x current ratio providing runway for clinical trials. Minimal debt burden with 0.00x debt-to-equity ratio reducing financial distress risk.
What are the risks of investing in BCAX?
Pre-revenue model with -$100.6M net loss and -$83.0M free cash flow indicating unsustainable burn rate. Approximately 2-year cash runway at current $82.9M annual operating burn rate requiring near-term financing or major clinical success.
What is BCAX's revenue and growth?
Bicara Therapeutics Inc. reported revenue of N/A.
Does BCAX pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
Where can I find BCAX SEC filings?
Official SEC filings for Bicara Therapeutics Inc. (CIK: 0002023658) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCAX's EPS?
Bicara Therapeutics Inc. has a diluted EPS of $-1.84.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.